Successful private placement of new Biocartis shares for 33 million EUR

Thursday, November 17, 2016 — On 17 November 2016, Biocartis, an innovative molecular diagnostics company, announced its intention to raise ca. € 25 million in a private placement through an accelerated book building, with the possibility to increase the size of the placement. The offering closed by noon on the same day.

Following strong demand and a significant oversubscription, it was decided to upsize the placement to € 33 million, and to price it at € 8.05 per share, implying a mere 2,4% discount versus the prior day closing price.

The new shares were mostly placed with Belgian and international institutional investors. In April 2015, Degroof Petercam already contributed to the successful IPO of Biocartis.

Degroof Petercam is once more very pleased with the success of this transaction, which demonstrates once again the commitment of Degroof Petercam towards life sciences companies and follows the other successful placement of MDxHealth in recent weeks.

About Degroof Petercam

Degroof Petercam is a reference financial institution with a history dating back to 1871. As an independent group owned by family shareholders with a long term commitment, we serve private and institutional investors.

Our clients benefit from a unique combination of services in private banking, institutional asset management , investment banking (corporate finance and financial intermediation) and asset services. We manage assets of more than 50 billion euro for private investors and families, corporates, pension funds, universities insurance companies, governmental and non-profit organizations.

Headquartered in Brussels, we employ 1 350 professionals through offices in Belgium, Luxemburg, France, Switzerland, Spain, The Netherlands, Germany, Italy, and Hong Kong.

Degroof Petercam
Rue de l'Industrie | Nijverheidsstraat 44
1040 Brussels